/

GKOS

Glaukos CorporationPre-market

168.02+2.33 +1.41%USD

NYSE · as of Oct 12, 16:00 ET · 20m delay

Open

166.79

Prev close

165.69

Day range

162.97171.16

52-week range

73.16191.62

Volume

799.29K0.94×

Mkt cap

9.91B

P/E ttm

—

Fwd P/E

320.45

EPS ttm

-3.26

Div yield

0.00%

Earnings

Oct 28, 2026

From 52w high

−12.32%

Price Chart

Yahoo Finance · delayed

GKOSOct 12, 2026O 166.79H 171.42L 162.97C 168.02+2.33 (+1.41%)Vol 881.90K

SMA 50172.77
SMA 200136.55

1Y change +103.51% since Oct 10, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

GKOS Glaukos Corporation · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: +2.44%
1 month: +0.46%
3 months: +10.02%
6 months: +40.61%
Year to date: +48.81%
1 year: +103.51%

Valuation & ownership

Market cap: 9.91B
Enterprise value: 9.73B
P/E (ttm): —
Forward P/E: 320.45
PEG ratio: —
Price / book: 14.49
Price / sales (ttm): 16.17
EV / EBITDA: -262.72
EPS (ttm): -3.26
EPS (forward): 0.5243
Beta (5y monthly): 0.69
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 58.98M
Float: 56.83M
Short % of float: 7.91%
Short ratio (days): 4.67
Held by insiders: 3.57%
Held by institutions: 105.39%
Avg volume (3m): 846.76K
50-day average: 172.77
200-day average: 136.55
52-week change: +103.51%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 52.3
vs 50-day SMA: −2.75%
vs 200-day SMA: +23.05%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▲ above
ATR (14) % of price: 4.84%
Realised vol (20d, ann.): 46.4%
From 52-week high: −12.32%
From 52-week low: +129.66%

ANR

Analyst Consensus

13 analysts

Consensus

Strong buy

1.36 on a 1 (strong buy) – 5 (sell) scale

Mean target

198.69

+18.26% implied

Low 172.00Median 200.00High 225.00

Recommendation trend

Now13 / 1 / 0
1m ago / 1 /

DES

About Glaukos Corporation

Yahoo Finance profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

Sector: Healthcare
Industry: Medical Devices
Employees: 1,094
Headquarters: Aliso Viejo, CA, United States
Website: glaukos.com
Officers

SEAS

Seasonality · GKOS

2015–2026 · monthly returns

Strongest month Jun +11.07%Weakest month Sep −3.19%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	5.7	0.9	-10.6	33.4	-28.1	35.2	19.3	7.7	-8.6	2.3			+48.8%
2025	4.3	-23.3	-18.0	-4.2	0.0	9.5	-16.7	11.3	-14.9	8.0	20.7	6.2	−24.7%
2024	12.0	-0.5	6.4	1.8	17.4	5.0	-1.0	14.3	-2.7	1.5	8.6	4.4	+88.6%
2023	12.3	-3.7	6.1	-5.2	20.0	24.9	8.3	-2.6	0.1	-9.4	-6.3	24.4	+82.0%
2022	19.8	3.9	4.5	-18.2	-13.7	11.2	18.6	-9.8	9.7	5.3	-16.9	-6.2	−1.7%
2021	17.8	6.6	-11.2	12.2	-21.9	15.3	-39.9	16.9	-19.2	-5.1	-5.9	3.3	−41.0%
2020	3.3	-21.8	-29.8	18.9	6.2	-1.4	13.7	9.5	3.5	12.9	20.7	11.5	+38.2%
2019	13.6	16.3	5.7	-8.0	-10.6	16.9	8.3	-21.3	-2.8	2.1	0.5	-15.1	−3.0%
2018	17.0	4.3	-1.5	9.2	12.1	7.6	2.4	64.3	-5.1	-10.7	13.7	-14.7	+119.0%
2017	20.2	10.4	12.7	-7.3	-14.3	1.9	-3.1	-6.0	-12.6	7.0	-24.2	-4.2	−25.2%
2016	-33.9	0.9	2.4	11.7	29.2	19.8	19.9	-14.6	26.5	-11.5	-6.6	9.9	+38.9%
2015							9.7	-7.6	-17.6	-17.2	29.2	-4.7	−14.8%

INSD

Insider Activity · GKOS

Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

173.8K shares

Sells, 6 months

175.5K shares

Net shares

−1.7K

Net change in insider shares

−0.10%

Date	Insider	Transaction	Shares	Value
Oct 4, 2026	Navratil TomasOfficer	Sale at price 163.93 - 165.60 per share.	1.5K	$251.12K
Sep 24, 2026	Navratil TomasOfficer	Sale at price 151.70 - 154.88 per share.	1.6K	$249.16K
Aug 27, 2026	Navratil TomasOfficer	Sale at price 180.25 - 182.50 per share.	13.7K	$2.48M
Aug 18, 2026	Kliman Gilbert H.Director	Sale at price 190.00 per share.	2.5K	$475.00K
Aug 18, 2026	Kliman Gilbert H.Director	Conversion of Exercise of derivative security at price 25.77 per share.	2.5K	$64.42K
Aug 10, 2026	Gilliam Joseph E.President	Sale at price 178.89 - 180.49 per share.	60K	$10.78M
Aug 10, 2026	Gilliam Joseph E.President	Conversion of Exercise of derivative security at price 48.46 - 55.18 per share.	60K	$3.18M
Aug 6, 2026	Thurman Alex R.Chief Financial Officer	Sale at price 180.13 per share.	20K	$3.60M
Aug 6, 2026	Thurman Alex R.Chief Financial Officer	Conversion of Exercise of derivative security at price 33.81 per share.	20K	$676.20K
Jul 30, 2026	Wen LeanaDirector	Sale at price 167.63 per share.	525	$88.01K
Jul 15, 2026	Thurman Alex R.Chief Financial Officer	Sale at price 160.00 per share.	10K	$1.60M
Jul 15, 2026	Thurman Alex R.Chief Financial Officer	Conversion of Exercise of derivative security at price 38.68 per share.	10K	$386.80K
Jul 8, 2026	Thurman Alex R.Chief Financial Officer	Sale at price 155.00 per share.	10K	$1.55M
Jul 8, 2026	Thurman Alex R.Chief Financial Officer	Conversion of Exercise of derivative security at price 38.68 per share.	10K	$386.80K
Jul 5, 2026	Thurman Alex R.Chief Financial Officer	Sale at price 150.00 per share.	10K	$1.50M
Jul 5, 2026	Thurman Alex R.Chief Financial Officer	Conversion of Exercise of derivative security at price 38.68 per share.	10K	$386.80K
Jun 30, 2026	Navratil TomasOfficer	Sale at price 139.06 per share.	716	$99.57K
Jun 15, 2026	Navratil TomasOfficer	Sale at price 130.68 per share.	1.5K	$200.85K
May 27, 2026	Kliman Gilbert H.Director	Stock Award(Grant) at price 0.00 per share.	1.9K	—
May 27, 2026	Kliman Gilbert H.Director	Stock Award(Grant) at price 0.00 per share.	1.9K	—

GKOS

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

GKOS

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Glaukos Corporation

Seasonality · GKOS

Insider Activity · GKOS

Congress Trades · GKOS

Congress Trades · GKOS

Insider Activity · GKOS

Seasonality · GKOS

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Glaukos Corporation

Financial Snapshot

Earnings & Dividends

News